Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CAD | P27708 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198286 | 0.86 | FOLH1 (0.39) | CPB2CYP1A2FOLH1SLC6A5SIRT6 | |
| SCHEMBL7198069 | 0.85 | CPB2 (0.45) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL7203331 | 0.83 | CPB2 (0.44) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL7198455 | 0.82 | CPB2 (0.43) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL25634935 | 0.81 | CPB2 (0.47) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL10296119 | 0.81 | CPB2 (0.47) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL7199195 | 0.81 | CPB2 (0.42) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL5814126 | 0.78 | SIRT6 (0.49) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL5814130 | 0.78 | SIRT6 (0.49) | CPB2CYP1A2KMT2APOLBCAD | |
| SCHEMBL7204362 | 0.77 | FOLH1 (0.50) | CPB2NOD1FOLH1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | CPB2 2478/4885CYP1A2 2332/4885KMT2A 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.